Phoenix, Arizona

FDA FORM 483 • INSPECTIONAL OBSERVATIONS

FDA Form 483: Case History, Documentation & Clinical Investigation Observations

A practical educational analysis of FDA inspection observations related to case-history accuracy, protocol compliance, subject eligibility, documentation practices and investigation controls.

⚠️ Important: FDA Form 483 Is an Inspectional Document

FDA Form 483 contains inspectional observations made by FDA investigators. The form itself states that these observations do not represent a final Agency determination regarding compliance.

This article therefore discusses the observations for educational, professional-development and regulatory-awareness purposes.

📋 FDA Inspection Overview

Document
Form FDA 483 – Inspectional Observations

Inspection Dates
March 9–13, 2026

FEI Number
3042366712

Individual / Firm Identified
Jeffrey R. Hoodin, M.D.

Location
Phoenix, Arizona

FDA District
Fairchild

🔎 What Are the Main Compliance Themes?

📑 Documentation Accuracy

Adequate and accurate case histories and records supporting the investigation.

🔐 Data Integrity

Records should allow an accurate reconstruction of study conduct.

🧪 Protocol Compliance

Investigational activities should be performed according to the signed investigator statement and investigational plan.

👥 Subject Eligibility

Eligibility and inclusion/exclusion requirements need appropriate documentation and verification.

FDA FORM 483 — OBSERVATION 1

Inadequate and Inaccurate Case Histories and Investigation Records

FDA Observation — Simplified Summary

The FDA investigator identified a failure to prepare and maintain adequate and accurate case histories containing observations and other data pertinent to the investigation for each enrolled subject.

1. Questionnaire Review and Investigator Oversight

The inspection documented that protocol-required questionnaires were not reviewed by the investigator at the time of each visit. The form states that study coordinators administered and reviewed a total of 76 assessments and were not delegated on the site delegation log to perform investigator review of those assessments.

The FDA documentation also describes repeated administration of assessments after the stated cutoff date and continued administration during subsequent visits.

Practical GMP / GCP Learning Point

Organizations should ensure that responsibilities for investigator review, study assessments and documentation are clearly assigned, appropriately delegated where applicable, and consistently performed according to the approved study requirements.

2. Conflicting and Irreconcilable Documentation

The FDA described conflicting accounts regarding whether a procedure was performed on a study subject. The inspection record describes differences between communications and later documentation concerning whether the procedure occurred, whether equipment was available and whether the subject participated.

The FDA characterized these discrepancies as demonstrating a failure to maintain adequate and accurate records as required by applicable regulations.

Why This Matters

When records contain conflicting accounts, investigators and reviewers may not be able to reliably reconstruct what actually happened during the study. This creates a significant documentation and data-integrity concern.

3. Contradictory Case-History Documentation

The FDA identified contradictory documentation concerning the timing and completion of inclusion/exclusion criteria assessments.

• Eligibility-related information was documented at different times.
• The inspection identified inconsistencies between screening, randomization and eligibility documentation.
• Laboratory results relevant to eligibility were described as pending at the time of a documented review/signature.
• The case history included incomplete and retrospectively completed documentation of inclusion/exclusion criteria.

4. Medical Record Verification Before Enrollment

The FDA observation also identified a failure to adequately review and verify medical records before enrollment to confirm eligibility.

The inspection record specifically describes enrollment before documented verification of medical records against an eligibility requirement.

5. Inadequate Documentation of Prior Medication Washout

The FDA also identified inadequate documentation concerning prior medication washout. The inspection record describes a situation in which a subject was randomized despite incomplete documentation and uncertainty concerning the required washout information.

🧭 Observation 1 — What Should a Strong Investigation Consider?

For educational purposes, a robust investigation of a similar issue should look beyond the individual documentation error and determine whether the problem represents a broader system weakness.

People

Were responsibilities understood, trained and appropriately assigned?

Procedure

Were procedures sufficiently clear regarding review, verification and documentation requirements?

Training

Did personnel understand when information had to be verified before enrollment or subsequent study activities?

Records

Can the records reconstruct what actually occurred and when?

Oversight

Was appropriate investigator and quality oversight performed?

Systemic Impact

Could similar documentation weaknesses exist in other subjects or studies?

FDA FORM 483 — OBSERVATION 2

Investigation Not Conducted According to the Signed Statement and Investigational Plan

FDA Observation — Simplified Summary

The FDA reported that an investigation was not conducted in accordance with the signed statement of investigator and investigational plan.

1. Enrollment of Subjects Who Did Not Meet Protocol Criteria

The inspection identified enrollment of subjects who did not meet protocol-specified eligibility criteria.

The FDA specifically describes an example involving an inclusion criterion and a subject whose screening information did not satisfy the required protocol condition.

2. Failure to Adjust Prohibited Concomitant Medication

The observation also identifies failure to appropriately manage prohibited concomitant medication in accordance with protocol requirements.

The FDA record describes a subject receiving medication and a subsequent failure to reduce the dose as required by the protocol.

Practical Learning Point

Protocol compliance must be actively controlled throughout the study. Eligibility verification is not merely an initial administrative activity; ongoing protocol requirements, medication restrictions and subject-specific criteria need appropriate review and documentation.

🔬 Root-Cause Investigation — Educational Framework

When similar findings occur, the investigation should determine why the control failed rather than stopping at the immediate documentation error. Potential areas for evaluation include:

1. Process Design
Was the process sufficiently defined?

2. Responsibility
Were roles and responsibilities clear?

3. Training
Was personnel competency adequate?

4. Documentation
Were records contemporaneous, complete and accurate?

5. Oversight
Was appropriate supervisory/investigator review performed?

6. Systemic Review
Could the same failure affect other subjects or studies?

🛠️ CAPA & Remediation — What Should Organizations Consider?

Immediate Correction

Identify and correct affected records and study activities through an appropriately documented process.

Retrospective Review

Assess whether similar deficiencies occurred in other subjects, visits or studies where appropriate.

Procedure Improvement

Strengthen procedures controlling eligibility, review, documentation and protocol compliance.

Training & Competency

Provide targeted training and verify that personnel understand their responsibilities.

Oversight

Strengthen investigator, study-management and quality oversight.

Effectiveness Check

Verify that corrective actions prevent recurrence and remain effective.

🛡️ What Can Other Pharmaceutical & Clinical Organizations Learn?

The educational value of an FDA Form 483 is not simply to identify deficiencies at another organization. It is to ask whether similar risks could exist within our own systems.

1. Can our records accurately reconstruct what happened, when it happened and who performed the activity?
2. Are eligibility and inclusion/exclusion requirements verified before subjects are enrolled?
3. Are investigator review responsibilities clearly defined and documented?
4. Are protocol deviations identified promptly and appropriately investigated?
5. Can retrospective documentation be distinguished clearly from contemporaneous records?
6. Are prohibited medications and other protocol restrictions actively controlled?
7. Do management and quality functions have sufficient oversight of clinical investigation activities?

💡 Key Takeaway

Accurate records + protocol compliance + appropriate oversight + effective investigation = stronger inspection readiness

📚 Related FDA Regulatory Resources

FDA Form 483

Explore additional FDA 483 inspection observations and practical regulatory learning.

FDA Warning Letters

Understand significant regulatory concerns communicated through FDA Warning Letters.

FDA Guidance

Explore FDA guidance and regulatory expectations relevant to pharmaceutical and clinical operations.

⚖️ Educational Disclaimer

This article is provided for educational and regulatory-awareness purposes only.

The FDA Form 483 observations discussed on this page are presented to help pharmaceutical, clinical research, quality and regulatory professionals understand inspection expectations, recognize potential compliance risks and strengthen their own systems.

PharmaceuticalMicrobiology.in does not intend to criticize, defame, discredit or negatively characterize the company, investigator, employees or any other individuals associated with the inspection.

Company and individual names are referenced only for identification of the publicly available FDA regulatory document being discussed. The observations are attributed to the FDA inspection document and should not be interpreted as an independent finding by PharmaceuticalMicrobiology.in.

FDA Form 483 contains inspectional observations and does not itself represent a final FDA determination regarding compliance. Readers should consult the original FDA documents, applicable regulations and official FDA guidance for authoritative information.

PharmaceuticalMicrobiology.in is an independent educational resource and is not affiliated with, operated by, or endorsed by the U.S. Food and Drug Administration (FDA).

ot Tag

PharmaceuticalMicrobiology.in
Learn from regulatory observations • Strengthen systems • Improve inspection readiness